Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 12/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1493493 | 0.88 | ALDH1A1 (0.47) | ALDH1A1TSHRLMNAALOX15MAPK1 | |
| SCHEMBL1612399 | 0.84 | P2RX7 (0.44) | ALDH1A1P2RX7KCNN4 | |
| SCHEMBL1493397 | 0.80 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL3295145 | 0.79 | KCNN4 (0.51) | ALDH1A1TSHRP2RX7KCNN4 | |
| SCHEMBL1493409 | 0.77 | ALDH1A1 (0.56) | ALDH1A1TSHRLMNAALOX15MAPK1 | |
| SCHEMBL1493429 | 0.77 | KCNN4 (0.37) | ALDH1A1TSHRP2RX7KCNN4 | |
| SCHEMBL1610810 | 0.73 | KCNN4 (0.40) | ALDH1A1TSHRLMNAALOX15MAPK1 | |
| SCHEMBL1493415 | 0.73 | TSHR (0.52) | ALDH1A1TSHRLMNAALOX15 | |
| SCHEMBL5685523 | 0.71 | MAPT (0.56) | ALDH1A1LMNAHTTHSD17B10 | |
| SCHEMBL5669758 | 0.70 | MAPT (0.61) | ALDH1A1TSHRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | ALDH1A1 3233/4885TSHR 44/4885LMNA 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.